Skip to main content
Delfa

← Trials/Trial dossier/NCT06052163

BumxAD

RecruitingPhase 2

Bumetanide in Patients With Alzheimer's Disease

Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease.

Asset

Bumetanide

Listed sites

1

Recruiting sites

1

Enrollment

40

estimated

Study population

Alzheimer’s disease

Key I/E criterion

•Alzheimer's disease

Primary endpoint

•Treatment-Related Adverse Events

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDIRB-69153
NCT IDNCT06052163

Timeline

Milestones

Study start2023-04-10actual
Study first posted2023-09-25actual
Last update posted2026-01-14actual
Primary completion2026-12-15estimated
Study completion2026-12-15estimated

Assets

Drug assets

Bumetanide

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years
Maximum age85 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Mild cognitive impairment or mild dementia due to Alzheimer's disease.
•Alzheimer's disease medications are planned to remain stable throughout.
•Willingness and ability to complete all aspects of the study including assessments, neuropsychological testing, and MRI

Exclusion criteria

•Clinically significant abnormalities in screening laboratory tests
•Chronic liver disease
•Renal insufficiency
•Poorly managed hypertension
•Participants taking the following concomitant medications, based on the current Prescribing Information for bumetanide: lithium, drugs with ototoxic potential, drugs with nephrotoxic potential, probenecid, and indomethacin.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition
2
Safety / tolerability / PK
1

Global cognition

2 endpoints
Secondary/protocol endpoint

Change from baseline in The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)

Time frame:6 months

ADAS-Cog

change from baseline, improvement

Secondary/protocol endpoint

Changed from baseline in the clinical dementia rating scale sum of boxes (CDR-SoB)

Time frame:6 months

Clinical Dementia Rating-Sum of Boxes (CDR-SB)

descriptive

Safety / tolerability / PK

1 endpoint
Primary/protocol endpoint

Incidence of Treatment-Related Adverse Events

Time frame:6 months

change from baseline, event

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.